On September 1, 2022 Genmab A/S (Nasdaq: GMAB) reported that its share buy-back program has been completed on August 31, 2022 (Press release, Genmab, SEP 1, 2022, View Source [SID1234618876]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program.

The share buy-back program was expected to be completed no later than August 31, 2022 and comprised up to 370,000 shares.

The following transactions were executed under the program from August 29, 2022 to August 31, 2022:

Details of each transaction are included as an appendix to this announcement.

Genmab’s accumulated share buy-back from June 20, 2022 to August 31, 2022 amounts to 370,000 shares at a total cost of DKK 907.49 million. The announced share buy-back program has thus been completed.

Following these transactions, Genmab holds 599,883 shares as treasury shares, corresponding to 0.91% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the "Safe Harbour Regulation." Further details on the terms of the share buy-back program can be found in our company announcement no. 22 dated June 17, 2022.